(LEGN) Legend Biotech - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.455m USD | Total Return: -0.1% in 12m
Avg Turnover: 49.0M
Qual. Beats: 0
Rev. Trend: 98.6%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -10.1 is critical
Altman Z'' -5.70 < 1.0 - financial distress zone
Choppy
Tailwinds
Confidence
Legend Biotech Corporation is a clinical-stage biopharmaceutical firm specializing in the development of chimeric antigen receptor (CAR-T) cell therapies. The company’s primary focus is oncology, specifically targeting multiple myeloma and various solid tumors through both autologous and allogeneic platforms. Its lead product, ciltacabtagene autoleucel (cilta-cel), is developed through a strategic collaboration with Janssen Biotech.
The CAR-T sector involves complex manufacturing processes where a patient’s T-cells are genetically engineered to recognize and attack specific cancer antigens. This personalized medicine business model often requires significant capital expenditure for specialized production facilities and cold-chain logistics to maintain cell viability. Legend Biotech further diversifies its pipeline through licensing agreements with global partners like Novartis to target solid tumor indications.
Investors can evaluate the long-term growth potential of these clinical assets by reviewing the detailed financial modeling available on ValueRay.
- Carvykti label expansion into second-line multiple myeloma treatment drives revenue growth
- Manufacturing capacity scaling for CAR-T therapies determines long-term commercial margins
- FDA regulatory decisions on cell therapy safety profiles influence investor sentiment
- Milestone payments from Janssen and Novartis partnerships provide essential capital inflows
- Clinical trial data for early-stage solid tumor pipeline dictates future valuation
| Net Income: -250.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 2.10 > 1.0 |
| NWC/Revenue: 50.37% < 20% (prev 135.2%; Δ -84.80% < -1%) |
| CFO/TA -0.11 > 3% & CFO -175.2m > Net Income -250.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (184.7m) vs 12m ago 0.53% < -2% |
| Gross Margin: 54.99% > 18% (prev 0.66%; Δ 5.43k% > 0.5%) |
| Asset Turnover: 70.90% > 50% (prev 45.08%; Δ 25.83% > 0%) |
| Interest Coverage Ratio: -10.08 > 6 (EBITDA TTM -181.1m / Interest Expense TTM 21.9m) |
| A: 0.36 (Total Current Assets 1.08b - Total Current Liabilities 509.1m) / Total Assets 1.60b |
| B: -1.26 (Retained Earnings -2.01b / Total Assets 1.60b) |
| C: -0.14 (EBIT TTM -220.4m / Avg Total Assets 1.61b) |
| D: -2.88 (Book Value of Equity -1.81b / Total Liabilities 629.0m) |
| Altman-Z'' = -5.70 = D |
| DSRI: 0.72 (Receivables 186.6m/166.8m, Revenue 1.14b/728.3m) |
| GMI: 1.19 (GM 54.99% / 65.51%) |
| AQI: 0.33 (AQ_t 0.04 / AQ_t-1 0.12) |
| SGI: 1.56 (Revenue 1.14b / 728.3m) |
| TATA: -0.05 (NI -250.2m - CFO -175.2m) / TA 1.60b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of May 29, 2026, the stock is trading at USD 28.26 with a total of 1,336,798 shares traded.
Over the past week, the price has changed by +0.50%,
over one month by +19.95%,
over three months by +48.74% and
over the past year by -0.11%.
Legend Biotech has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LEGN.
- StrongBuy: 11
- Buy: 10
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 55.4 | 96% |
P/E Forward = 196.0784
P/S = 4.7894
P/B = 5.643
Revenue TTM = 1.14b USD
EBIT TTM = -220.4m USD
EBITDA TTM = -181.1m USD
Long Term Debt = 112.1m USD (estimated: total debt 389.3m - short term 277.2m)
Short Term Debt = 277.2m USD (from shortTermDebt, last quarter)
Debt = 512.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 123.3m
Net Debt = -322.0m USD (calculated: Debt 512.6m - CCE 834.6m)
Enterprise Value = 5.13b USD (5.46b + Debt 512.6m - CCE 834.6m)
Interest Coverage Ratio = -10.08 (Ebit TTM -220.4m / Interest Expense TTM 21.9m)
EV/FCF = -21.72x (Enterprise Value 5.13b / FCF TTM -236.4m)
FCF Yield = -4.60% (FCF TTM -236.4m / Enterprise Value 5.13b)
FCF Margin = -20.75% (FCF TTM -236.4m / Revenue TTM 1.14b)
Net Margin = -21.97% (Net Income TTM -250.2m / Revenue TTM 1.14b)
Gross Margin = 54.99% ((Revenue TTM 1.14b - Cost of Revenue TTM 512.7m) / Revenue TTM)
Gross Margin QoQ = 42.35% (prev 59.70%)
Tobins Q-Ratio = 3.21 (Enterprise Value 5.13b / Total Assets 1.60b)
Interest Expense / Debt = 4.27% (Interest Expense 21.9m / Debt 512.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -174.1m (EBIT -220.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.13 (Total Current Assets 1.08b / Total Current Liabilities 509.1m)
Debt / Equity = 0.53 (Debt 512.6m / totalStockholderEquity, last quarter 967.7m)
Debt / EBITDA = 1.78 (negative EBITDA) (Net Debt -322.0m / EBITDA -181.1m)
Debt / FCF = 1.36 (negative FCF - burning cash) (Net Debt -322.0m / FCF TTM -236.4m)
Total Stockholder Equity = 1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = -15.58% (Net Income -250.2m / Total Assets 1.60b)
RoE = -8.29% (Net Income TTM -250.2m / Total Stockholder Equity 3.02b)
RoCE = -7.04% (EBIT -220.4m / Capital Employed (Equity 3.02b + L.T.Debt 112.1m))
RoIC = -13.43% (negative operating profit) (NOPAT -174.1m / Invested Capital 1.30b)
WACC = 7.63% (E(5.46b)/V(5.97b) * Re(8.03%) + D(512.6m)/V(5.97b) * Rd(4.27%) * (1-Tc(0.21)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.32 | Cagr: 5.22%
[DCF] Fair Price = unknown (Cash Flow -236.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.55 | # QB: 0
Revenue Correlation: 98.61 | Revenue CAGR: 97.20% | SUE: -0.04 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.28 | Chg30d=+411.11% | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.10 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=0.28 | Chg30d=+351.61% | Revisions=N/A | GrowthEPS=+117.5% | GrowthRev=+40.2%
EPS next Year (2027-12-31): EPS=1.24 | Chg30d=+11.01% | Revisions=N/A | GrowthEPS=+344.1% | GrowthRev=+26.4%